AbbVie Signs an Exclusive Worldwide Research Collaboration with Voyager Therapeutics for Vectorized Abs

 AbbVie Signs an Exclusive Worldwide Research Collaboration with Voyager Therapeutics for Vectorized Abs

AbbVie Signs an Exclusive Worldwide Research Collaboration with Voyager Therapeutics for Vectorized Abs

Shots:

  • Voyager to receive $65M upfront and will be responsible for research, IND submission and onset of P-I trial for targets provided by AbbVie. AbbVie to get a WW option to license rights to futher develop and commercialize one or more vectorized alpha-synuclein Abs for Parkinson’s and other synucleinopathies
  • If AbbVie exercises its option to license, Voyager will receive $245M as P-I option, $1.2B milestones including regulatory & commercial sales and royalties on global sales of products
  • Voyager’s technology is an AVV gene therapy technology enabling the development of therapies utilizing blood-brain barrier penetrant AVV capsids in neurological disorders including Parkinson’s disease, Alzheimer’s disease, Huntington’s disease & Friedreich’s ataxia

Click here to read full press release/ article | Ref: AbbVie | Image: Twipu

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post